{"ticker": {"uuid": "f9b5e3a3-6ae2-454c-b837-016afc8974b7", "symbol": "KURA", "name": "Kura Oncology Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Kura Oncology to Present First Long-Term Follow-Up Data", "summary": "Kura Oncology will present updated Phase 1a results from its FIT-001 clinical trial at the 2026 Kidney Cancer Research Summit, showcasing long-term follow-up data for darlifarnib in combination with cabozantinib for advanced renal cell carcinoma. The data aims to support darlifar", "url": "https://www.globenewswire.com/news-release/2026/07/14/3326716/0/en/Kura-Oncology-to-Present-First-Long-Term-Follow-Up-Data-Further-Supporting-Darlifarnib-s-Potential-to-Enhance-VEGFR-Targeted-Therapy-in-Renal-Cell-Carcinoma-at-KCRS-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T19:13:51", "published_display": "14 Jul 2026 19:13", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Kura Oncology, Inc. \u2013 NASDAQ:KURA", "summary": "This article provides a specific financial metric, \"Enterprise value to revenue forward,\" for Kura Oncology, Inc. (NASDAQ: KURA). It is presented within the context of TradingView's financial data offerings, indicating the company's listing on the Nasdaq Stock Market. The content", "url": "https://www.tradingview.com/symbols/NASDAQ-KURA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T16:14:27", "published_display": "14 Jul 2026 16:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology presents new data supporting darlifarnib's role in enhancing kidney cancer therapy.", "summary": "Kura Oncology released updated Phase 1a results from its FIT-001 trial, showing that darlifarnib combined with cabozantinib improved outcomes for advanced clear cell renal cell carcinoma (ccRCC) patients. These findings suggest darlifarnib enhances VEGFR-targeted therapies, with ", "url": "https://pluang.com/en/news-feed/kura-oncology-paparkan-data-lanjutan-darlifarnib-tingkatkan-terapi-vegrf-renal", "source_name": "Pluang", "published_at": "2026-07-14T11:14:27", "published_display": "14 Jul 2026 11:14", "sentiment": "positive", "sentiment_pct": 90, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib\u2019s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026", "summary": "Kura Oncology announced it will present updated Phase 1a results from the FIT-001 clinical trial evaluating darlifarnib in combination with cabozantinib at the 2026 Kidney Cancer Research Summit. These long-term follow-up data in advanced renal cell carcinoma patients are expecte", "url": "https://www.globenewswire.com/news-release/2026/07/14/3326716/35186/en/Kura-Oncology-to-Present-First-Long-Term-Follow-Up-Data-Further-Supporting-Darlifarnib-s-Potential-to-Enhance-VEGFR-Targeted-Therapy-in-Renal-Cell-Carcinoma-at-KCRS-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T11:14:27", "published_display": "14 Jul 2026 11:14", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Kura Oncology, Inc. \u2013 NASDAQ:KURA", "summary": "This article provides a financial listing for Kura Oncology, Inc. (NASDAQ: KURA) on TradingView, focusing on its price to earnings forward. It shows the company's stock information, market status, and available financial data points.", "url": "https://www.tradingview.com/symbols/NASDAQ-KURA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T20:11:10", "published_display": "13 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "(KURA) and the Role of Price-Sensitive Allocations", "summary": "This article provides a detailed analysis of Kura Oncology Inc. (NASDAQ: KURA), highlighting strong sentiment across all horizons and identifying a mid-channel oscillation pattern. It presents three distinct AI-generated trading strategies tailored for different risk profiles: Po", "url": "https://news.stocktradersdaily.com/news_release/132/KURA_and_the_Role_of_Price-Sensitive_Allocations_071126022001_1783750801.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-11T02:20:00", "published_display": "11 Jul 2026 02:20", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Kura Oncology, Inc. \u2013 NASDAQ:KURA", "summary": "This article displays the \"Price to sales forward\" metric for Kura Oncology, Inc. (NASDAQ: KURA). It provides a snapshot of this financial data point for the company, accessible through TradingView's financial analysis tools. The content focuses solely on presenting this particul", "url": "https://www.tradingview.com/symbols/NASDAQ-KURA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T08:10:16", "published_display": "09 Jul 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology (KURA) Is Up 9.3% After Shift From Russell Value To Growth Indices - What's Changed", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-08T14:42:56+00:00", "published_display": "08 Jul 2026 14:42", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Kura Oncology\u2019s (KURA) Shift Into Russell Growth Indexes Redefine Its Core Investment Story?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/does-kura-oncology-kura-shift-220903282.html", "source_name": "Simply Wall St.", "published_at": "2026-07-07T22:09:03+00:00", "published_display": "07 Jul 2026 22:09", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology outlines targeted cancer pipeline as investors watch clinical milestones", "summary": "Kura Oncology Inc. is a biotech company focused on developing targeted therapies for difficult-to-treat cancers. The company's strategy involves advancing small-molecule drugs through clinical trials for genetically defined cancer subsets, a common approach in the US oncology sec", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/kura-oncology-outlines-targeted-cancer-pipeline-as-investors-watch/69715125", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T14:11:19", "published_display": "07 Jul 2026 14:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Sushi (NASDAQ:KRUS) Misses Q2 CY2026 Revenue Estimates, Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPQVdNcHNKYS1vRURIX1ZLNExqZnczZF9hS1N2YUFLNlo3eEs0TlEzb0lsQzZHUFd2cmhERkZ2Z05DME1ZSi0tRU9IbklVMFh1dEhBQURsdElwSk96Y25UanNaeURid1JwV1paZWNKbzNuTVZqRFNWQWxBSFRUS0poYXJ6bFY5T2xOOUFEZEVza2QwOUFmSkpsMGZB?oc=5", "source_name": "Market source", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology offers stock options to five new hires", "summary": "Kura Oncology announced the grant of nonstatutory stock options for 68,750 shares to five new employees on July 1, 2026, with an exercise price of $10.78 per share. These inducement grants are made under the company's 2023 Inducement Option Plan, as amended, and align with Nasdaq", "url": "https://www.stocktitan.net/news/KURA/kura-oncology-reports-inducement-grants-under-nasdaq-listing-rule-54weg1wtd17o.html", "source_name": "Stock Titan", "published_at": "2026-07-03T11:39:17", "published_display": "03 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Kura Oncology, Inc. announced that its Compensation Committee granted inducement awards to five new employees. These awards consist of nonstatutory stock options to purchase 68,750 shares of common stock, with an exercise price of $10.78 per share, vesting over four years. This a", "url": "https://www.globenewswire.com/news-release/2026/07/03/3321791/35186/en/kura-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html", "source_name": "GlobeNewswire", "published_at": "2026-07-03T11:39:17", "published_display": "03 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KURA News | KURA ONCOLOGY INC (NASDAQ:KURA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE9hOWZmRUI3SkFtVWY3dEhjQ0dDQkJLZFZCYW5ucWFKa296VUhzQW82NExTdlU4UHd4c2NNYzBFREhKUVJRcG1ISlpNX0NodUZ2OE1fOEQzY2d4MVk?oc=5", "source_name": "ChartMill", "published_at": "2026-07-03T00:00:02+00:00", "published_display": "03 Jul 2026 00:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology Reports Q1 2026 Results: Full Earnings Call Transcript", "summary": "Kura Oncology reported Q1 2026 net product revenue of $5.8 million for Comzifty, exceeding expectations in its first full quarter since commercial launch. The company emphasizes expanding Comzifty's use across the AML treatment spectrum, including combination therapies, and antic", "url": "https://www.benzinga.com/news/26/07/60236845/kura-oncology-reports-q1-2026-results-full-earnings-call-transcript", "source_name": "Benzinga", "published_at": "2026-07-02T06:12:23", "published_display": "02 Jul 2026 06:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology, Inc.(NasdaqGS:KURA) added to Russell Small Cap Comp Growth Benchmark", "summary": "Kura Oncology, Inc. (NasdaqGS:KURA) has been added to the Russell Small Cap Comp Growth Benchmark, along with the Russell 2500 Growth and Russell 3000E Growth Benchmarks. The biopharmaceutical company, focused on precision medicine for cancer treatment, was also dropped from the ", "url": "https://www.marketscreener.com/news/kura-oncology-inc-nasdaqgs-kura-added-to-russell-small-cap-comp-growth-benchmark-ce7f5fdfdd81ff23", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T21:48:00", "published_display": "29 Jun 2026 21:48", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology, Inc.(NasdaqGS: KURA) added to Russell 2500 Growth Benchmark", "summary": "Kura Oncology, Inc. (NasdaqGS: KURA) has been added to the Russell 2500 Growth Benchmark, as announced on June 29, 2026. This inclusion reflects the company's growth trajectory and highlights its position within the small-cap growth market. Kura Oncology is a clinical-stage bioph", "url": "https://www.marketscreener.com/news/kura-oncology-inc-nasdaqgs-kura-added-to-russell-2500-growth-benchmark-ce7f5fdfda81fe23", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T19:09:13", "published_display": "29 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology, Inc. liabilities 2021-2025", "summary": "This article from Statista presents data on the liabilities of Kura Oncology, Inc. from 2021 to 2025. The company's liabilities are reported to have continuously increased from 2021 to 2025, reaching a specific amount in 2025, according to data from their fiscal year ending Decem", "url": "https://www.statista.com/statistics/1503615/kura-oncology-inc-liabilities/", "source_name": "Statista", "published_at": "2026-06-26T14:10:04", "published_display": "26 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology, Inc. Actuals & Estimates (NASDAQ:KURA)", "summary": "This article provides an overview of Kura Oncology, Inc. (NASDAQ: KURA) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the company's market capitalization, upcoming earnings report, and recent financial results, su", "url": "https://www.tradingview.com/symbols/NASDAQ-KURA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T13:43:39", "published_display": "26 Jun 2026 13:43", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology, Inc. Actuals & Estimates (DUS:KUR)", "summary": "This article provides an overview of Kura Oncology, Inc. (DUS:KUR) stock, including financial data, analyst estimates, historical prices, and future earnings reports. It details the company's past earnings and revenue, current EBITDA, and confirms that it does not pay dividends.", "url": "https://www.tradingview.com/symbols/DUS-KUR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T12:39:14", "published_display": "26 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology, Inc. Actuals & Estimates (HAM:KUR)", "summary": "This article provides an overview of Kura Oncology, Inc. (HAM:KUR) financial data, analyst estimates, and stock performance. It includes details on revenue, earnings, EBITDA, stock forecasts, and historical price movements, alongside answers to frequently asked questions about th", "url": "https://www.tradingview.com/symbols/HAM-KUR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:10:30", "published_display": "26 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Kura Sushi (NASDAQ:KRUS) In The Context Of Other Sit-Down Dining Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOanFfczR1UGlpM3IydzVaWEVlaTJNdjYySGl1WG1HbHJfWTZqRkJwMWw2dko5U1ZUdjNLbnotZm9IbUo3Rk5USGdRdy1LMXE5VFZyTkdvVkhZVG1BRVp0RXBmZnFRMkdHV1BVQjZjUVJpdGt4LVNVMHBnR2NnN21USlBXZkp4cDZ1T3BtbV9rbGl1ZlNfaXhVM2ZtVFpEdw?oc=5", "source_name": "Market source", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insiders At Kura Oncology Sold US$1.5m In Stock, Alluding To Potential Weakness", "summary": "Kura Oncology (NASDAQ:KURA) saw its insiders sell US$1.5 million worth of stock over the last year, indicating a potential weakness in the company's outlook. This sell-off occurred despite a generally flat share price, with analysts expecting the company to become profitable in t", "url": "https://www.moomoo.com/news/post/71904815/insiders-at-kura-oncology-sold-us-1-5m-in-stock", "source_name": "Moomoo", "published_at": "2026-06-23T14:09:38", "published_display": "23 Jun 2026 14:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology CMO Mollie Leoni sells $834,283 in common stock By Investing.com", "summary": "Mollie Leoni, CMO of Kura Oncology, sold 84,929 shares of company stock for approximately $834,283. These shares were acquired through restricted stock units and sold under a Rule 10b5-1 trading plan. The sale follows a strong 77% return for KURA shares over the past year and com", "url": "https://m.za.investing.com/news/stock-market-news/kura-oncology-cmo-mollie-leoni-sells-834283-in-common-stock-93CH-4338903?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-06-23T02:09:38", "published_display": "23 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Kura Oncology Inc For: 22 June By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Kura Oncology Inc. The filing was made on June 22nd and the article provides no further details beyond this announcement. The core content is simply the title and a repetition of the details within the body.", "url": "https://ng.investing.com/news/stock-market-news/form-4-kura-oncology-inc-for-22-june-93CH-2568978", "source_name": "Investing.com Nigeria", "published_at": "2026-06-22T22:40:47", "published_display": "22 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology (NASDAQ: KURA) CMO sells 84,929 shares in trading plan", "summary": "Kura Oncology's Chief Medical Officer, Mollie Leoni, sold 84,929 shares of common stock on June 18, 2026, at a weighted average price of $9.8233 per share, totaling approximately $834,283. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 19, ", "url": "https://www.stocktitan.net/sec-filings/KURA/form-4-kura-oncology-inc-insider-trading-activity-80d7fb6f19ba.html", "source_name": "Stock Titan", "published_at": "2026-06-22T21:59:48", "published_display": "22 Jun 2026 21:59", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding the Setup: (KURA) and Scalable Risk", "summary": "The article provides an analysis of Kura Oncology Inc. (NASDAQ: KURA), highlighting positive near-term sentiment that may counter a mid-term weak bias within a long-term strong trend. It points out that resistance is being tested and details specific trading strategies for differ", "url": "https://news.stocktradersdaily.com/news_release/141/Understanding_the_Setup:_KURA_and_Scalable_Risk_061926120001_1781841602.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-19T00:10:08", "published_display": "19 Jun 2026 00:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Kura Oncology, Inc. SEC Filing", "summary": "This article details a Form 144 SEC filing by Kura Oncology, Inc. for a proposed sale of securities. The filing indicates a sale of 84,929 shares of common stock with an aggregate market value of $812,770.53 through Morgan Stanley Smith Barney LLC on NASDAQ, dated June 18, 2026. ", "url": "https://www.stocktitan.net/sec-filings/KURA/144-kura-oncology-inc-sec-filing-16e6e91236dc.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:10:08", "published_display": "18 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology Inc (KURA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Kura Oncology Inc (KURA) has an earnings forecast score of 8.25. Analysts have given KURA a strong buy rating with an average price target of $28.00, ranging from $16.00 to $76.00. The company's expected revenue for the next quarter is $20.84 million, with an expected EPS of -$0.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kura/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T10:10:54", "published_display": "18 Jun 2026 10:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology Inc (KURA) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Kura Oncology Inc (KURA) has a weak financial status and low operating efficiency, ranking 320 out of 388 in the Biotechnology & Medical Research industry with a financial score of 5.85. Despite this, its latest quarterly revenue increased by 29.47% year-over-year to $18.27 milli", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kura/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T01:40:54", "published_display": "17 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology Inc (KURA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Kura Oncology Inc (KURA), focusing on its business segments and regional revenue contributions. However, it states that relevant financial data for FY2024, FY2025, and specific quarters have not yet been disclosed by the company. The ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kura/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T01:11:03", "published_display": "17 Jun 2026 01:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology, Kyowa Kirin Cancer Combo Therapy Extends Survival in AML Patients", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kura-oncology-kyowa-kirin-cancer-125502067.html", "source_name": "MT Newswires", "published_at": "2026-06-11T12:55:02+00:00", "published_display": "11 Jun 2026 12:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kura-oncology-kyowa-kirin-report-120200213.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T12:02:00+00:00", "published_display": "11 Jun 2026 12:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Kura Oncology (KURA) Investment Narrative Is Evolving Without New Analyst Revisions", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/kura-oncology-kura-investment-narrative-080710414.html", "source_name": "Simply Wall St.", "published_at": "2026-06-06T08:07:10+00:00", "published_display": "06 Jun 2026 08:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology Plans Wider Platform Study for Darlifarnib Amid Recent Data on Anti-Tumor Activity", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kura-oncology-plans-wider-platform-115348457.html", "source_name": "MT Newswires", "published_at": "2026-06-03T11:53:48+00:00", "published_display": "03 Jun 2026 11:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology Highlights Darlifarnib\u2019s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kura-oncology-highlights-darlifarnib-potential-105300472.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T10:53:00+00:00", "published_display": "03 Jun 2026 10:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kura-oncology-kyowa-kirin-announce-123200504.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T12:32:00+00:00", "published_display": "02 Jun 2026 12:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology stock (US50126D1028): FDA breakthrough nod and pipeline update draw investor focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOdzdKT3ZOZEtIME1BNl94TlE4OFYyYUNDeDZMclNqMUVZbnlWcUxkRkhhclAwUEJucHZzSjRFZ185Z2NGSlQ1aThSWVRtb0FNSTJLbW9lV2U3Q1JmSWRDb29NaHFfb09FRlhFRVZuVURPeWZ6UmtIWUFINlh2TFc4dFBQaGVjSGMtSzVfSDZUY2Fib2FtaGhBV1M0NXJnUHJqa0JfdUNnRXoyX1pFQUZPa0N6X0pEUUhKNktYQkdYOFN3cnM?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Some Analysts Just Cut Their Kura Oncology, Inc. (NASDAQ:KURA) Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPZ1RXNW55Z2o2WW15Q2t2Q0l1b0pvZS1EUmxadzczRnM1R2dNTE0tQWVZUThDd3lxSjZuR2k2eUdiLUQ5LUQ0Y3A3M2tNY2VwR1ZnOTYxR2JsMFdkMUxzbnBiZ3JxREpGZWlUNkg2ekg3QnJjYUNSSXJxU3lxUmxPdVI4bWVKNFcwZ24xdDBic0lIMkhGSXp1dXVERHM?oc=5", "source_name": "Market source", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Kura Oncology, Inc. (NASDAQ:KURA) Just Reported And Analysts Are Trimming Their Forecasts", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPdTU1TjdMZDhMd29WRkZsd1pPU3czQzRYemhQN1RHZ0xaNmxfUko0REFSMTRzbWk4ci1HYzFpcDJuM3c5VW4ybWRPYTVFWlBoTDFXQXIxMFU2eDlfdEFXUDFFZXkzSGxELS1xQVZSVzBlMThlM1kxOXYtWUZ1ZU1BVXpPVldHY2ZlYlFWenhoTnc5bW9xNURYLUNGQVRYOEE?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Have Lowered Expectations For Kura Oncology, Inc. (NASDAQ:KURA) After Its Latest Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Kura Oncology stock (US50126D1028): Q1 earnings beat and analyst buys", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOSHk3SWlEb2RtWTBER2oxT2V0dUtxTHhYcVM1MXVGQXFHTGtOWFp5V210aTViQ1lzNGFDUXZ3MzBlclFQTE0zcXpKZHk2TnNtbXhhd2xXejNDaU0wODRqS0JZTkhQUklheEtRaHV4eW83N25BeVpvcnRtOW5EOHE0dUFXcHdzelN1SHUtSjlESkl5Vl93N09MR0JydnVMazIzQjRrZmtkWjU3dERPci1GMTc1N2hpbGlfQ3lHYWt3c1Q0SVU?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Kura Oncology (KURA) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOaTc5RXlEMUlJOEJvV18tcnR5MmhNb2ppZEFUUjFNSk5SOUdqdmhBdnZYZ1BRcjlLak9qaWJRei1WdUtBSm53c0xvT0dMUnRFQ3lRTVdENTJuZnNTRWVlNFFiZVlxb01Uc2dnRU0zd2Npb0hFemdxMms0b1dRNGF4d0VDVEV4VUJ1UkhzUXZvN21LQlU4Tm5jb00tTWxZdw?oc=5", "source_name": "Market source", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Kura Oncology (KURA) Moves 8.3% Higher: Will This Strength Last?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPWnRldEV3SjhVTTJHVHFBd2ZvN2I5d2dhb0VEYlpjdDJxekZYZFBOTmRCUF9PWVgtckc5Z3JQQWhhWVBNVjFWeHdOTnNzenR0Wkp6T1NpU1Y1a2JlM2RzRWQ1U01adDNYcEkzNFp5QUlZN0VHcmVveXU4YXB1SV9TWEJRX2Mta2dHSm5TMkpGTF9URmxETXc?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology: Poised For A Lift With Combinations (NASDAQ:KURA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOWUNDR0VnQ292cEN3SGEwSUJNck9ab2Z2NWpsQi1SSHRoQUZLTVNIZ3pHVVNESy1sTlRNNjJKOUh3YmU0d1RFYUprcXlyTWp4aWwwWWdsWi1SSkVieGRtVmRrRTJRbGVGRks5VXNOeUc0S004dXlhaWVvamg5QXJKLXR5VUhseF9HRWFLREE3UlN2SDdS?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Need To Know: The Consensus Just Cut Its Kura Oncology, Inc. (NASDAQ:KURA) Estimates For 2026", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Don't Ignore The Insider Selling In Kura Oncology", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-29T08:00:00+00:00", "published_display": "29 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology: A Cautious Buy (NASDAQ:KURA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE1Bb1JISnNfMmVkNWVNRks4dVlhTVE5VVA5YlhsLXd1SjZSVmt0WUM0eVE5NkdQa1RwV1ZLZnhEaVZOeWdBbWtpRjB0ckdTblVwLURKeFJ6aXY5Zmk3VmNibEtyU1QwU19FT2tINEFSc3hRZElkWnlXMA?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-12-04T08:00:00+00:00", "published_display": "04 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Komzifti Gains FDA Approval, Giving Kura Oncology and Kyowa Kirin a Key Strategic Win in NPM1-Mutated AML", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPYlhUanloMmdtNHBlcXA2MHNBZUZJXzRJQTNNOUE1amFEcTJuZWRRY3dXNW82Q1VNWW1yNTlaNlBTM3A2bEFYYzZ0a0xjczlDaHhuTDhkM1ZaN3VJMEZPLWFXNFFOZU5WOUFvNk5ubHJ3Skx1Z1kwRDRMVTBTY0lhVS1ZRmhZZzR1LTVOeDltUGdIVktnbm9JSjk5TQ?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2025-11-14T08:00:00+00:00", "published_display": "14 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA approves Kura-Kyowa's blood cancer therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPY3ZZQVFvT0Iya2xMU3lqWHM2bzVJYVBUNnhtX2M1Vnc1bTdsdnlzSTYwZlB5MDJvaU5tZWNRbFpSbzlXNmNMUHlqbnpmaGl5OXRKOHdKWGF4aGVabjVGVno0VlRDMjN2SGVmSS1pRndRRVNXLU9zNGstSUFOY2ZPWjVhWU5ZQTkzemp6S1VyYXBJaDJzcHdnRGRNZnZCR0FhTTVIcFFMSGZnczlHVm10SGljS0lKMmJsc2xxQkN6ekg?oc=5", "source_name": "Reuters", "published_at": "2025-11-13T08:00:00+00:00", "published_display": "13 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgJBVV95cUxQa2xKWk9vMktOYUN3dGF4akpGVjNwcUZsVU9USlZBZXEwT3B3RTBCT1NFWjdtbFN2TDRNSnpSbFYxQUxDbFdCcTBGd05hVjJtZjcyR180N2M0SHZXaUwtWEhnaEdVVUYxRzZjRmxKUWJYUldoeVV5UUpaandNYnFjYlhSUTQ0ZXN5Q3J6VW9oNnVNLUFHTkNGdk9HR0VneTNDd2pvSm1WYTNFX181ZUpVZXE2X2wyTUhackp3SFBIbGJ6VzJMaDEyb2huRVB5Vl9ER2s3Z2Y1NWdHS3U4UXJPVGN5TmxkemE1QWdiRUZxcjBrWjRtZWw0Q3lkNjBPMUlCUUY0TGJNcXNwc3J3cDN2eDZ3?oc=5", "source_name": "PR Newswire", "published_at": "2024-11-20T08:00:00+00:00", "published_display": "20 Nov 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Kura Oncology to Present First Long-Term Follow-Up Data", "summary": "Kura Oncology will present updated Phase 1a results from its FIT-001 clinical trial at the 2026 Kidney Cancer Research Summit, showcasing long-term follow-up data for darlifarnib in combination with cabozantinib for advanced renal cell carcinoma. The data aims to support darlifar", "url": "https://www.globenewswire.com/news-release/2026/07/14/3326716/0/en/Kura-Oncology-to-Present-First-Long-Term-Follow-Up-Data-Further-Supporting-Darlifarnib-s-Potential-to-Enhance-VEGFR-Targeted-Therapy-in-Renal-Cell-Carcinoma-at-KCRS-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T19:13:51", "published_display": "14 Jul 2026 19:13", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Kura Oncology, Inc. \u2013 NASDAQ:KURA", "summary": "This article provides a specific financial metric, \"Enterprise value to revenue forward,\" for Kura Oncology, Inc. (NASDAQ: KURA). It is presented within the context of TradingView's financial data offerings, indicating the company's listing on the Nasdaq Stock Market. The content", "url": "https://www.tradingview.com/symbols/NASDAQ-KURA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T16:14:27", "published_display": "14 Jul 2026 16:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology presents new data supporting darlifarnib's role in enhancing kidney cancer therapy.", "summary": "Kura Oncology released updated Phase 1a results from its FIT-001 trial, showing that darlifarnib combined with cabozantinib improved outcomes for advanced clear cell renal cell carcinoma (ccRCC) patients. These findings suggest darlifarnib enhances VEGFR-targeted therapies, with ", "url": "https://pluang.com/en/news-feed/kura-oncology-paparkan-data-lanjutan-darlifarnib-tingkatkan-terapi-vegrf-renal", "source_name": "Pluang", "published_at": "2026-07-14T11:14:27", "published_display": "14 Jul 2026 11:14", "sentiment": "positive", "sentiment_pct": 90, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib\u2019s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026", "summary": "Kura Oncology announced it will present updated Phase 1a results from the FIT-001 clinical trial evaluating darlifarnib in combination with cabozantinib at the 2026 Kidney Cancer Research Summit. These long-term follow-up data in advanced renal cell carcinoma patients are expecte", "url": "https://www.globenewswire.com/news-release/2026/07/14/3326716/35186/en/Kura-Oncology-to-Present-First-Long-Term-Follow-Up-Data-Further-Supporting-Darlifarnib-s-Potential-to-Enhance-VEGFR-Targeted-Therapy-in-Renal-Cell-Carcinoma-at-KCRS-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T11:14:27", "published_display": "14 Jul 2026 11:14", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Kura Oncology, Inc. \u2013 NASDAQ:KURA", "summary": "This article provides a financial listing for Kura Oncology, Inc. (NASDAQ: KURA) on TradingView, focusing on its price to earnings forward. It shows the company's stock information, market status, and available financial data points.", "url": "https://www.tradingview.com/symbols/NASDAQ-KURA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T20:11:10", "published_display": "13 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(KURA) and the Role of Price-Sensitive Allocations", "summary": "This article provides a detailed analysis of Kura Oncology Inc. (NASDAQ: KURA), highlighting strong sentiment across all horizons and identifying a mid-channel oscillation pattern. It presents three distinct AI-generated trading strategies tailored for different risk profiles: Po", "url": "https://news.stocktradersdaily.com/news_release/132/KURA_and_the_Role_of_Price-Sensitive_Allocations_071126022001_1783750801.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-11T02:20:00", "published_display": "11 Jul 2026 02:20", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Kura Oncology, Inc. \u2013 NASDAQ:KURA", "summary": "This article displays the \"Price to sales forward\" metric for Kura Oncology, Inc. (NASDAQ: KURA). It provides a snapshot of this financial data point for the company, accessible through TradingView's financial analysis tools. The content focuses solely on presenting this particul", "url": "https://www.tradingview.com/symbols/NASDAQ-KURA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T08:10:16", "published_display": "09 Jul 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology (KURA) Is Up 9.3% After Shift From Russell Value To Growth Indices - What's Changed", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-08T14:42:56+00:00", "published_display": "08 Jul 2026 14:42", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Kura Oncology\u2019s (KURA) Shift Into Russell Growth Indexes Redefine Its Core Investment Story?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/does-kura-oncology-kura-shift-220903282.html", "source_name": "Simply Wall St.", "published_at": "2026-07-07T22:09:03+00:00", "published_display": "07 Jul 2026 22:09", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology outlines targeted cancer pipeline as investors watch clinical milestones", "summary": "Kura Oncology Inc. is a biotech company focused on developing targeted therapies for difficult-to-treat cancers. The company's strategy involves advancing small-molecule drugs through clinical trials for genetically defined cancer subsets, a common approach in the US oncology sec", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/kura-oncology-outlines-targeted-cancer-pipeline-as-investors-watch/69715125", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T14:11:19", "published_display": "07 Jul 2026 14:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Sushi (NASDAQ:KRUS) Misses Q2 CY2026 Revenue Estimates, Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPQVdNcHNKYS1vRURIX1ZLNExqZnczZF9hS1N2YUFLNlo3eEs0TlEzb0lsQzZHUFd2cmhERkZ2Z05DME1ZSi0tRU9IbklVMFh1dEhBQURsdElwSk96Y25UanNaeURid1JwV1paZWNKbzNuTVZqRFNWQWxBSFRUS0poYXJ6bFY5T2xOOUFEZEVza2QwOUFmSkpsMGZB?oc=5", "source_name": "Market source", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology offers stock options to five new hires", "summary": "Kura Oncology announced the grant of nonstatutory stock options for 68,750 shares to five new employees on July 1, 2026, with an exercise price of $10.78 per share. These inducement grants are made under the company's 2023 Inducement Option Plan, as amended, and align with Nasdaq", "url": "https://www.stocktitan.net/news/KURA/kura-oncology-reports-inducement-grants-under-nasdaq-listing-rule-54weg1wtd17o.html", "source_name": "Stock Titan", "published_at": "2026-07-03T11:39:17", "published_display": "03 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Kura Oncology, Inc. announced that its Compensation Committee granted inducement awards to five new employees. These awards consist of nonstatutory stock options to purchase 68,750 shares of common stock, with an exercise price of $10.78 per share, vesting over four years. This a", "url": "https://www.globenewswire.com/news-release/2026/07/03/3321791/35186/en/kura-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html", "source_name": "GlobeNewswire", "published_at": "2026-07-03T11:39:17", "published_display": "03 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KURA News | KURA ONCOLOGY INC (NASDAQ:KURA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE9hOWZmRUI3SkFtVWY3dEhjQ0dDQkJLZFZCYW5ucWFKa296VUhzQW82NExTdlU4UHd4c2NNYzBFREhKUVJRcG1ISlpNX0NodUZ2OE1fOEQzY2d4MVk?oc=5", "source_name": "ChartMill", "published_at": "2026-07-03T00:00:02+00:00", "published_display": "03 Jul 2026 00:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology Reports Q1 2026 Results: Full Earnings Call Transcript", "summary": "Kura Oncology reported Q1 2026 net product revenue of $5.8 million for Comzifty, exceeding expectations in its first full quarter since commercial launch. The company emphasizes expanding Comzifty's use across the AML treatment spectrum, including combination therapies, and antic", "url": "https://www.benzinga.com/news/26/07/60236845/kura-oncology-reports-q1-2026-results-full-earnings-call-transcript", "source_name": "Benzinga", "published_at": "2026-07-02T06:12:23", "published_display": "02 Jul 2026 06:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology, Inc.(NasdaqGS:KURA) added to Russell Small Cap Comp Growth Benchmark", "summary": "Kura Oncology, Inc. (NasdaqGS:KURA) has been added to the Russell Small Cap Comp Growth Benchmark, along with the Russell 2500 Growth and Russell 3000E Growth Benchmarks. The biopharmaceutical company, focused on precision medicine for cancer treatment, was also dropped from the ", "url": "https://www.marketscreener.com/news/kura-oncology-inc-nasdaqgs-kura-added-to-russell-small-cap-comp-growth-benchmark-ce7f5fdfdd81ff23", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T21:48:00", "published_display": "29 Jun 2026 21:48", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology, Inc.(NasdaqGS: KURA) added to Russell 2500 Growth Benchmark", "summary": "Kura Oncology, Inc. (NasdaqGS: KURA) has been added to the Russell 2500 Growth Benchmark, as announced on June 29, 2026. This inclusion reflects the company's growth trajectory and highlights its position within the small-cap growth market. Kura Oncology is a clinical-stage bioph", "url": "https://www.marketscreener.com/news/kura-oncology-inc-nasdaqgs-kura-added-to-russell-2500-growth-benchmark-ce7f5fdfda81fe23", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T19:09:13", "published_display": "29 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology, Inc. liabilities 2021-2025", "summary": "This article from Statista presents data on the liabilities of Kura Oncology, Inc. from 2021 to 2025. The company's liabilities are reported to have continuously increased from 2021 to 2025, reaching a specific amount in 2025, according to data from their fiscal year ending Decem", "url": "https://www.statista.com/statistics/1503615/kura-oncology-inc-liabilities/", "source_name": "Statista", "published_at": "2026-06-26T14:10:04", "published_display": "26 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology, Inc. Actuals & Estimates (NASDAQ:KURA)", "summary": "This article provides an overview of Kura Oncology, Inc. (NASDAQ: KURA) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the company's market capitalization, upcoming earnings report, and recent financial results, su", "url": "https://www.tradingview.com/symbols/NASDAQ-KURA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T13:43:39", "published_display": "26 Jun 2026 13:43", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology, Inc. Actuals & Estimates (DUS:KUR)", "summary": "This article provides an overview of Kura Oncology, Inc. (DUS:KUR) stock, including financial data, analyst estimates, historical prices, and future earnings reports. It details the company's past earnings and revenue, current EBITDA, and confirms that it does not pay dividends.", "url": "https://www.tradingview.com/symbols/DUS-KUR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T12:39:14", "published_display": "26 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology, Inc. Actuals & Estimates (HAM:KUR)", "summary": "This article provides an overview of Kura Oncology, Inc. (HAM:KUR) financial data, analyst estimates, and stock performance. It includes details on revenue, earnings, EBITDA, stock forecasts, and historical price movements, alongside answers to frequently asked questions about th", "url": "https://www.tradingview.com/symbols/HAM-KUR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:10:30", "published_display": "26 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Kura Sushi (NASDAQ:KRUS) In The Context Of Other Sit-Down Dining Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOanFfczR1UGlpM3IydzVaWEVlaTJNdjYySGl1WG1HbHJfWTZqRkJwMWw2dko5U1ZUdjNLbnotZm9IbUo3Rk5USGdRdy1LMXE5VFZyTkdvVkhZVG1BRVp0RXBmZnFRMkdHV1BVQjZjUVJpdGt4LVNVMHBnR2NnN21USlBXZkp4cDZ1T3BtbV9rbGl1ZlNfaXhVM2ZtVFpEdw?oc=5", "source_name": "Market source", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insiders At Kura Oncology Sold US$1.5m In Stock, Alluding To Potential Weakness", "summary": "Kura Oncology (NASDAQ:KURA) saw its insiders sell US$1.5 million worth of stock over the last year, indicating a potential weakness in the company's outlook. This sell-off occurred despite a generally flat share price, with analysts expecting the company to become profitable in t", "url": "https://www.moomoo.com/news/post/71904815/insiders-at-kura-oncology-sold-us-1-5m-in-stock", "source_name": "Moomoo", "published_at": "2026-06-23T14:09:38", "published_display": "23 Jun 2026 14:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology CMO Mollie Leoni sells $834,283 in common stock By Investing.com", "summary": "Mollie Leoni, CMO of Kura Oncology, sold 84,929 shares of company stock for approximately $834,283. These shares were acquired through restricted stock units and sold under a Rule 10b5-1 trading plan. The sale follows a strong 77% return for KURA shares over the past year and com", "url": "https://m.za.investing.com/news/stock-market-news/kura-oncology-cmo-mollie-leoni-sells-834283-in-common-stock-93CH-4338903?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-06-23T02:09:38", "published_display": "23 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Kura Oncology Inc For: 22 June By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Kura Oncology Inc. The filing was made on June 22nd and the article provides no further details beyond this announcement. The core content is simply the title and a repetition of the details within the body.", "url": "https://ng.investing.com/news/stock-market-news/form-4-kura-oncology-inc-for-22-june-93CH-2568978", "source_name": "Investing.com Nigeria", "published_at": "2026-06-22T22:40:47", "published_display": "22 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology (NASDAQ: KURA) CMO sells 84,929 shares in trading plan", "summary": "Kura Oncology's Chief Medical Officer, Mollie Leoni, sold 84,929 shares of common stock on June 18, 2026, at a weighted average price of $9.8233 per share, totaling approximately $834,283. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 19, ", "url": "https://www.stocktitan.net/sec-filings/KURA/form-4-kura-oncology-inc-insider-trading-activity-80d7fb6f19ba.html", "source_name": "Stock Titan", "published_at": "2026-06-22T21:59:48", "published_display": "22 Jun 2026 21:59", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding the Setup: (KURA) and Scalable Risk", "summary": "The article provides an analysis of Kura Oncology Inc. (NASDAQ: KURA), highlighting positive near-term sentiment that may counter a mid-term weak bias within a long-term strong trend. It points out that resistance is being tested and details specific trading strategies for differ", "url": "https://news.stocktradersdaily.com/news_release/141/Understanding_the_Setup:_KURA_and_Scalable_Risk_061926120001_1781841602.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-19T00:10:08", "published_display": "19 Jun 2026 00:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Kura Oncology, Inc. SEC Filing", "summary": "This article details a Form 144 SEC filing by Kura Oncology, Inc. for a proposed sale of securities. The filing indicates a sale of 84,929 shares of common stock with an aggregate market value of $812,770.53 through Morgan Stanley Smith Barney LLC on NASDAQ, dated June 18, 2026. ", "url": "https://www.stocktitan.net/sec-filings/KURA/144-kura-oncology-inc-sec-filing-16e6e91236dc.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:10:08", "published_display": "18 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology Inc (KURA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Kura Oncology Inc (KURA) has an earnings forecast score of 8.25. Analysts have given KURA a strong buy rating with an average price target of $28.00, ranging from $16.00 to $76.00. The company's expected revenue for the next quarter is $20.84 million, with an expected EPS of -$0.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kura/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T10:10:54", "published_display": "18 Jun 2026 10:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology Inc (KURA) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Kura Oncology Inc (KURA) has a weak financial status and low operating efficiency, ranking 320 out of 388 in the Biotechnology & Medical Research industry with a financial score of 5.85. Despite this, its latest quarterly revenue increased by 29.47% year-over-year to $18.27 milli", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kura/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T01:40:54", "published_display": "17 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology Inc (KURA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Kura Oncology Inc (KURA), focusing on its business segments and regional revenue contributions. However, it states that relevant financial data for FY2024, FY2025, and specific quarters have not yet been disclosed by the company. The ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kura/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T01:11:03", "published_display": "17 Jun 2026 01:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology, Kyowa Kirin Cancer Combo Therapy Extends Survival in AML Patients", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kura-oncology-kyowa-kirin-cancer-125502067.html", "source_name": "MT Newswires", "published_at": "2026-06-11T12:55:02+00:00", "published_display": "11 Jun 2026 12:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kura-oncology-kyowa-kirin-report-120200213.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T12:02:00+00:00", "published_display": "11 Jun 2026 12:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Kura Oncology (KURA) Investment Narrative Is Evolving Without New Analyst Revisions", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/kura-oncology-kura-investment-narrative-080710414.html", "source_name": "Simply Wall St.", "published_at": "2026-06-06T08:07:10+00:00", "published_display": "06 Jun 2026 08:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology Plans Wider Platform Study for Darlifarnib Amid Recent Data on Anti-Tumor Activity", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kura-oncology-plans-wider-platform-115348457.html", "source_name": "MT Newswires", "published_at": "2026-06-03T11:53:48+00:00", "published_display": "03 Jun 2026 11:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology Highlights Darlifarnib\u2019s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kura-oncology-highlights-darlifarnib-potential-105300472.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T10:53:00+00:00", "published_display": "03 Jun 2026 10:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kura-oncology-kyowa-kirin-announce-123200504.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T12:32:00+00:00", "published_display": "02 Jun 2026 12:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology stock (US50126D1028): FDA breakthrough nod and pipeline update draw investor focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOdzdKT3ZOZEtIME1BNl94TlE4OFYyYUNDeDZMclNqMUVZbnlWcUxkRkhhclAwUEJucHZzSjRFZ185Z2NGSlQ1aThSWVRtb0FNSTJLbW9lV2U3Q1JmSWRDb29NaHFfb09FRlhFRVZuVURPeWZ6UmtIWUFINlh2TFc4dFBQaGVjSGMtSzVfSDZUY2Fib2FtaGhBV1M0NXJnUHJqa0JfdUNnRXoyX1pFQUZPa0N6X0pEUUhKNktYQkdYOFN3cnM?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Some Analysts Just Cut Their Kura Oncology, Inc. (NASDAQ:KURA) Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPZ1RXNW55Z2o2WW15Q2t2Q0l1b0pvZS1EUmxadzczRnM1R2dNTE0tQWVZUThDd3lxSjZuR2k2eUdiLUQ5LUQ0Y3A3M2tNY2VwR1ZnOTYxR2JsMFdkMUxzbnBiZ3JxREpGZWlUNkg2ekg3QnJjYUNSSXJxU3lxUmxPdVI4bWVKNFcwZ24xdDBic0lIMkhGSXp1dXVERHM?oc=5", "source_name": "Market source", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Kura Oncology, Inc. (NASDAQ:KURA) Just Reported And Analysts Are Trimming Their Forecasts", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPdTU1TjdMZDhMd29WRkZsd1pPU3czQzRYemhQN1RHZ0xaNmxfUko0REFSMTRzbWk4ci1HYzFpcDJuM3c5VW4ybWRPYTVFWlBoTDFXQXIxMFU2eDlfdEFXUDFFZXkzSGxELS1xQVZSVzBlMThlM1kxOXYtWUZ1ZU1BVXpPVldHY2ZlYlFWenhoTnc5bW9xNURYLUNGQVRYOEE?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Have Lowered Expectations For Kura Oncology, Inc. (NASDAQ:KURA) After Its Latest Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxQV1ctbDllZ2RILVJxMlJrVjV4M2hhbGhpaUdyMENsSmpsUk5EZnYtcGtsdTBKbXBVSEk0TjZ5dm1DR3BMN3ItVGdiN3BjdkE2WFpUUFR6Q0s1VlUtNExTMTN1UDIxdUxnZDJ5M19MeGVlc2lZck02LXkyYXdmOS1ZN1lTcmxWSVZQLVlYM01XbzNLWTlPWU9pTUwwbHM5SzNoRjA2bmlPclM4ZHJ2WGFzMDdEZm9sb1FaQ0xzeWYzclN3VzZJdVN1ZmRMbzhPZHYyekpTNlpTQU9hMUFoRDJhT9IB5gFBVV95cUxNZEFCNzJrMkxDcUtPSG5acmw1WlR2aEllRXhVQVdKTWgxWkdxaUpsSGxVX08xSzlGalBKbmNNRFBZaEZxX3AxVFFneVREa21DUTBHVXNDdGprd2xOMEw2SUhXbENlNEp2bUlRQmJIbGoyT1Z2OGVsaUhoZ3owRmo5OE9Vank3TkdoVFpod3RrSmVOU091bE9ONzVINWhON1BNY2o5cV9xcmZlbk8wcm9CR2xxdnVMYlRvSWMxcTdUYV96bDlvV0dFWkhqSXItS0lMTGt2dmh2Ni1rSDBJakN2ejRqSDFfZw?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology stock (US50126D1028): Q1 earnings beat and analyst buys", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOSHk3SWlEb2RtWTBER2oxT2V0dUtxTHhYcVM1MXVGQXFHTGtOWFp5V210aTViQ1lzNGFDUXZ3MzBlclFQTE0zcXpKZHk2TnNtbXhhd2xXejNDaU0wODRqS0JZTkhQUklheEtRaHV4eW83N25BeVpvcnRtOW5EOHE0dUFXcHdzelN1SHUtSjlESkl5Vl93N09MR0JydnVMazIzQjRrZmtkWjU3dERPci1GMTc1N2hpbGlfQ3lHYWt3c1Q0SVU?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology (KURA) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOaTc5RXlEMUlJOEJvV18tcnR5MmhNb2ppZEFUUjFNSk5SOUdqdmhBdnZYZ1BRcjlLak9qaWJRei1WdUtBSm53c0xvT0dMUnRFQ3lRTVdENTJuZnNTRWVlNFFiZVlxb01Uc2dnRU0zd2Npb0hFemdxMms0b1dRNGF4d0VDVEV4VUJ1UkhzUXZvN21LQlU4Tm5jb00tTWxZdw?oc=5", "source_name": "Market source", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology (KURA) Moves 8.3% Higher: Will This Strength Last?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPWnRldEV3SjhVTTJHVHFBd2ZvN2I5d2dhb0VEYlpjdDJxekZYZFBOTmRCUF9PWVgtckc5Z3JQQWhhWVBNVjFWeHdOTnNzenR0Wkp6T1NpU1Y1a2JlM2RzRWQ1U01adDNYcEkzNFp5QUlZN0VHcmVveXU4YXB1SV9TWEJRX2Mta2dHSm5TMkpGTF9URmxETXc?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology: Poised For A Lift With Combinations (NASDAQ:KURA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOWUNDR0VnQ292cEN3SGEwSUJNck9ab2Z2NWpsQi1SSHRoQUZLTVNIZ3pHVVNESy1sTlRNNjJKOUh3YmU0d1RFYUprcXlyTWp4aWwwWWdsWi1SSkVieGRtVmRrRTJRbGVGRks5VXNOeUc0S004dXlhaWVvamg5QXJKLXR5VUhseF9HRWFLREE3UlN2SDdS?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Need To Know: The Consensus Just Cut Its Kura Oncology, Inc. (NASDAQ:KURA) Estimates For 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxNSjZPaVFHSkN1azQzZmpjdzJpYUVvdE5XYkZxdXMtcGNhTnAxQXR3NGhoRnVHVmViSWpUSl9YTFVNckN3Vnc4TUsxd3dUQ3I4SG1lTDNLRGJKRmFvMlZudVlLaTdmZ2ZQbFU0Q2xycjdEa3BCMms1MTYyay00a1RvcDByRmhkbVNnTDBfcnM4SFQ4WFktY0I0WEtHTnpueWtqb19mQVJ1Nlg4VUlYY3pneUxMamtFTERORThGdUlrRk1tNmMydFo1S3ZCcUhMWUVjamlUanpjWUVGbkJZMW50TtIB5gFBVV95cUxPbTdVV0ZhQTdScVlWRGgzYzZXbU1aMV9EVkJEQ2ZJdWZQN1NqRWx6RmNCcnRLWVltdU8yODFqS3lNYjBieGNfc3hoQjZ0SkZBd0F5S1pvVE5vLTNlWEx6dmdUZVZjV09BNzFpcUExa3Y4YzVFN0xTaGc3U0I1dHlLTFJISlFnSy1qT3Y3TXpBNGEtWkhaNnZJOEI4ajJfVWtwSDREZ0Q1d3hmMVJiajR4alg1anZWaHZxM2N1QzRFN04wRVdndG5JU2ZWYnF6SDF0em41TWFWSHlvX3cwcGVnRkozRWk1dw?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Don't Ignore The Insider Selling In Kura Oncology", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-29T08:00:00+00:00", "published_display": "29 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology: A Cautious Buy (NASDAQ:KURA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE1Bb1JISnNfMmVkNWVNRks4dVlhTVE5VVA5YlhsLXd1SjZSVmt0WUM0eVE5NkdQa1RwV1ZLZnhEaVZOeWdBbWtpRjB0ckdTblVwLURKeFJ6aXY5Zmk3VmNibEtyU1QwU19FT2tINEFSc3hRZElkWnlXMA?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-12-04T08:00:00+00:00", "published_display": "04 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Komzifti Gains FDA Approval, Giving Kura Oncology and Kyowa Kirin a Key Strategic Win in NPM1-Mutated AML", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPYlhUanloMmdtNHBlcXA2MHNBZUZJXzRJQTNNOUE1amFEcTJuZWRRY3dXNW82Q1VNWW1yNTlaNlBTM3A2bEFYYzZ0a0xjczlDaHhuTDhkM1ZaN3VJMEZPLWFXNFFOZU5WOUFvNk5ubHJ3Skx1Z1kwRDRMVTBTY0lhVS1ZRmhZZzR1LTVOeDltUGdIVktnbm9JSjk5TQ?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2025-11-14T08:00:00+00:00", "published_display": "14 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA approves Kura-Kyowa's blood cancer therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPY3ZZQVFvT0Iya2xMU3lqWHM2bzVJYVBUNnhtX2M1Vnc1bTdsdnlzSTYwZlB5MDJvaU5tZWNRbFpSbzlXNmNMUHlqbnpmaGl5OXRKOHdKWGF4aGVabjVGVno0VlRDMjN2SGVmSS1pRndRRVNXLU9zNGstSUFOY2ZPWjVhWU5ZQTkzemp6S1VyYXBJaDJzcHdnRGRNZnZCR0FhTTVIcFFMSGZnczlHVm10SGljS0lKMmJsc2xxQkN6ekg?oc=5", "source_name": "Reuters", "published_at": "2025-11-13T08:00:00+00:00", "published_display": "13 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgJBVV95cUxQa2xKWk9vMktOYUN3dGF4akpGVjNwcUZsVU9USlZBZXEwT3B3RTBCT1NFWjdtbFN2TDRNSnpSbFYxQUxDbFdCcTBGd05hVjJtZjcyR180N2M0SHZXaUwtWEhnaEdVVUYxRzZjRmxKUWJYUldoeVV5UUpaandNYnFjYlhSUTQ0ZXN5Q3J6VW9oNnVNLUFHTkNGdk9HR0VneTNDd2pvSm1WYTNFX181ZUpVZXE2X2wyTUhackp3SFBIbGJ6VzJMaDEyb2huRVB5Vl9ER2s3Z2Y1NWdHS3U4UXJPVGN5TmxkemE1QWdiRUZxcjBrWjRtZWw0Q3lkNjBPMUlCUUY0TGJNcXNwc3J3cDN2eDZ3?oc=5", "source_name": "PR Newswire", "published_at": "2024-11-20T08:00:00+00:00", "published_display": "20 Nov 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 108, "total_relevant": 59, "sentiment_summary": {"positive": 21, "negative": 7, "neutral": 31, "score": 56, "total": 59, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 16.45, "count": 28}, {"event": "earnings", "label": "Earnings", "weight": 13.75, "count": 27}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 21, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 11.45, "latest_week": "2026-07-10", "one_week_move": 3.2, "four_week_move": 26.5, "twelve_week_move": 18.3, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.029709, "market_dynamics_buy_signal": false, "relative_strength": 7.902348, "fair_value_gap": -5.0, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 49.387, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+3.2% over one week, +26.5% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 64, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 11}, {"label": "TradingView", "count": 7}, {"label": "GlobeNewswire", "count": 6}, {"label": "simplywall.st", "count": 6}, {"label": "Stock Titan", "count": 3}, {"label": "TradingKey", "count": 3}, {"label": "Stock Traders Daily", "count": 2}, {"label": "Simply Wall St.", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 51}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 28}, {"label": "Earnings", "count": 27}, {"label": "Regulatory and legal", "count": 2}, {"label": "Guidance", "count": 1}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "51", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+3.2% over one week, +26.5% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Kura Oncology to Present First Long-Term Follow-Up Data"}], "updated_at": "2026-07-16T11:52:28.210802+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}